Aura Biosciences (AURA)
Aura Biosciences on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances).
10.9M
Short interest
settlement 2026-10-15
10.6
Days to cover
+1.4 days vs prior
69.9%
Short share of volume
2026-11-02
8,026
Fails to deliver
settlement 2026-10-14
Thu 12 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in AURA is 10,885,962 shares, up 3,835,989 shares over the last month. Over the last 48 readings it ranged from 947,110 shares (15 November 2024) to 10,885,962 shares (15 October 2026). The latest reading sits at the top of that range. At the reported average volume of 1.0M shares a day that is 10.6 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/aura" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 10,885,962 | +5.0% | 1,023,787 | 10.63 |
| 2026-09-30 | 10,366,122 | +47.0% | 1,122,555 | 9.23 |
| 2026-09-15 | 7,049,973 | +13.7% | 604,730 | 11.66 |
| 2026-08-31 | 6,203,498 | +0.7% | 972,230 | 6.38 |
| 2026-08-14 | 6,158,945 | -3.1% | 622,079 | 9.90 |
| 2026-07-31 | 6,358,049 | +13.4% | 344,394 | 18.46 |
| 2026-07-15 | 5,608,945 | -19.1% | 692,744 | 8.10 |
| 2026-06-30 | 6,932,229 | +28.7% | 742,197 | 9.34 |
| 2026-06-15 | 5,386,870 | +43.1% | 521,877 | 10.32 |
| 2026-05-29 | 3,762,979 | +19.2% | 496,436 | 7.58 |
| 2026-05-15 | 3,156,446 | +44.0% | 1,134,937 | 2.78 |
| 2026-04-30 | 2,192,556 | +8.9% | 275,247 | 7.97 |
| 2026-04-15 | 2,013,075 | -23.0% | 327,990 | 6.14 |
| 2026-03-31 | 2,615,841 | +4.3% | 295,408 | 8.86 |
| 2026-03-13 | 2,508,348 | +11.5% | 282,536 | 8.88 |
| 2026-02-27 | 2,249,277 | -22.1% | 208,040 | 10.81 |
| 2026-02-13 | 2,885,504 | -8.8% | 187,755 | 15.37 |
| 2026-01-30 | 3,163,686 | -0.9% | 181,042 | 17.47 |
| 2026-01-15 | 3,192,788 | +0.6% | 178,833 | 17.85 |
| 2025-12-31 | 3,172,944 | +3.7% | 204,805 | 15.49 |
| 2025-12-15 | 3,058,660 | -5.3% | 149,017 | 20.53 |
| 2025-11-28 | 3,231,139 | +10.6% | 243,342 | 13.28 |
| 2025-11-14 | 2,922,667 | -0.0% | 199,832 | 14.63 |
| 2025-10-31 | 2,922,993 | -7.0% | 302,693 | 9.66 |
| 2025-10-15 | 3,143,743 | +0.3% | 264,142 | 11.90 |
| 2025-09-30 | 3,135,369 | +7.3% | 364,978 | 8.59 |
| 2025-09-15 | 2,921,687 | +4.6% | 171,910 | 17.00 |
| 2025-08-29 | 2,792,413 | +1.9% | 144,973 | 19.26 |
| 2025-08-15 | 2,741,256 | -0.8% | 145,826 | 18.80 |
| 2025-07-31 | 2,762,438 | +1.9% | 172,659 | 16.00 |
| 2025-07-15 | 2,710,073 | +1.6% | 142,928 | 18.96 |
| 2025-06-30 | 2,667,208 | -1.9% | 298,335 | 8.94 |
| 2025-06-13 | 2,719,214 | +3.0% | 203,559 | 13.36 |
| 2025-05-30 | 2,639,447 | +10.3% | 247,600 | 10.66 |
| 2025-05-15 | 2,393,160 | +10.6% | 228,610 | 10.47 |
| 2025-04-30 | 2,164,228 | +10.8% | 158,838 | 13.63 |
| 2025-04-15 | 1,953,589 | +37.8% | 333,293 | 5.86 |
| 2025-03-31 | 1,417,847 | +18.7% | 579,618 | 2.45 |
| 2025-03-14 | 1,194,732 | +6.2% | 162,115 | 7.37 |
| 2025-02-28 | 1,124,623 | -13.0% | 148,541 | 7.57 |
| 2025-02-14 | 1,293,150 | +6.5% | 141,789 | 9.12 |
| 2025-01-31 | 1,214,164 | -13.9% | 130,612 | 9.30 |
| 2025-01-15 | 1,410,114 | +10.2% | 134,831 | 10.46 |
| 2024-12-31 | 1,279,272 | +20.4% | 197,791 | 6.47 |
| 2024-12-13 | 1,062,598 | +2.7% | 170,753 | 6.22 |
| 2024-11-29 | 1,034,773 | +9.3% | 293,517 | 3.53 |
| 2024-11-15 | 947,110 | -16.1% | 163,591 | 5.79 |
| 2024-10-31 | 1,128,562 | +7.4% | 290,627 | 3.88 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of AURA volume is 69.9%, up 5.8 points over the last five sessions. Over the last 30 readings it ranged from 27.8% (20 October 2026) to 91.0% (16 October 2026). The latest reading is in line with the 30-session average of 68.5%, on 239K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 167K | 239K | 69.9% | 3,018 |
| 2026-10-30 | 147K | 196K | 74.9% | 201 |
| 2026-10-29 | 210K | 367K | 57.3% | 0 |
| 2026-10-28 | 105K | 129K | 81.3% | 0 |
| 2026-10-27 | 111K | 232K | 48.1% | 0 |
| 2026-10-26 | 180K | 281K | 64.0% | 0 |
| 2026-10-23 | 198K | 293K | 67.5% | 0 |
| 2026-10-22 | 169K | 435K | 38.9% | 23 |
| 2026-10-21 | 192K | 415K | 46.4% | 0 |
| 2026-10-20 | 141K | 507K | 27.8% | 0 |
| 2026-10-19 | 112K | 140K | 80.0% | 0 |
| 2026-10-16 | 246K | 271K | 91.0% | 419 |
| 2026-10-15 | 189K | 212K | 89.2% | 0 |
| 2026-10-14 | 390K | 430K | 90.7% | 0 |
| 2026-10-13 | 481K | 602K | 79.9% | 0 |
| 2026-10-12 | 146K | 217K | 67.1% | 0 |
| 2026-10-09 | 213K | 297K | 71.5% | 348 |
| 2026-10-08 | 314K | 390K | 80.7% | 0 |
| 2026-10-07 | 126K | 234K | 53.7% | 0 |
| 2026-10-06 | 139K | 186K | 74.9% | 0 |
| 2026-10-05 | 119K | 179K | 66.5% | 0 |
| 2026-10-02 | 568K | 697K | 81.5% | 0 |
| 2026-10-01 | 163K | 298K | 54.7% | 1,247 |
| 2026-09-30 | 152K | 204K | 74.1% | 0 |
| 2026-09-29 | 212K | 309K | 68.6% | 312 |
| 2026-09-28 | 117K | 169K | 69.7% | 0 |
| 2026-09-25 | 236K | 513K | 46.0% | 0 |
| 2026-09-24 | 311K | 360K | 86.2% | 0 |
| 2026-09-23 | 351K | 450K | 78.0% | 0 |
| 2026-09-22 | 110K | 147K | 74.5% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 14 October 2026, the fails-to-deliver balance in AURA is 8,026 shares, up 2,741 shares over the last settlement date. Over the last 30 readings it ranged from 32 shares (9 April 2026) to 117,323 shares (29 June 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-14 | 8,026 | $6.27 | $50K |
| 2026-10-13 | 5,285 | $6.54 | $35K |
| 2026-10-09 | 1,125 | $6.51 | $7K |
| 2026-10-07 | 2,383 | $6.17 | $15K |
| 2026-10-01 | 391 | $6.28 | $2K |
| 2026-08-31 | 3,602 | $7.40 | $27K |
| 2026-08-25 | 451 | $7.90 | $4K |
| 2026-08-20 | 58 | $7.79 | $452 |
| 2026-08-06 | 4,374 | $7.18 | $31K |
| 2026-07-29 | 13,376 | $7.05 | $94K |
| 2026-06-30 | 117,260 | $6.88 | $807K |
| 2026-06-29 | 117,323 | $7.00 | $821K |
| 2026-06-26 | 36 | $6.86 | $247 |
| 2026-06-25 | 116,177 | $7.04 | $818K |
| 2026-06-17 | 6,484 | $6.28 | $41K |
| 2026-06-16 | 23,302 | $6.45 | $150K |
| 2026-06-12 | 388 | $6.21 | $2K |
| 2026-06-11 | 388 | $6.12 | $2K |
| 2026-06-10 | 384 | $6.35 | $2K |
| 2026-05-07 | 2,070 | $8.29 | $17K |
| 2026-04-22 | 942 | $7.44 | $7K |
| 2026-04-09 | 32 | $6.77 | $217 |
| 2026-03-24 | 264 | $6.53 | $2K |
| 2026-03-09 | 6,189 | $5.60 | $35K |
| 2026-03-04 | 693 | $6.24 | $4K |
| 2026-03-03 | 7,054 | $6.14 | $43K |
| 2026-03-02 | 911 | $5.89 | $5K |
| 2026-02-19 | 34 | $5.04 | $171 |
| 2026-02-18 | 34 | $5.25 | $179 |
| 2026-02-17 | 34 | $5.57 | $189 |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for AURA in the last 90 days. The most recent filings are listed below. Latest filing: Kratz Erica (Chief Reg. & Quality Officer) on 2026-09-01.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-01 | Kratz Erica | Chief Reg. & Quality Officer | Grant | 101K | $0.00 | $0 | 101K |
| 2026-09-01 | Elazzouzi Amy | SVP, Finance & PAO | Grant | 24K | $0.00 | $0 | 144K |
| 2026-09-01 | Hopkins Janet Jill | Chief Medical Officer | Grant | 59K | $0.00 | $0 | 380K |
| 2026-09-01 | Person Julie | Chief People Officer | Grant | 108K | $0.00 | $0 | 108K |
| 2026-09-01 | Abu-Absi Susan | Chief Operating Officer | Grant | 135K | $0.00 | $0 | 135K |
| 2026-07-07 | Bender Jeremy | Director | Grant | 30K | $0.00 | $0 | 30K |
| 2026-07-01 | Kilroy Conor | See Remarks | Grant | 15K | $0.00 | $0 | 233K |
| 2026-06-16 | Gibney Anthony S | See Remarks | Sell | 13K | $6.42 | $82K | 265K |
| 2026-06-11 | Bitetti Teresa Marie | Director | Grant | 15K | $0.00 | $0 | 36K |
| 2026-06-11 | Srivastava Sapna | Director | Grant | 15K | $0.00 | $0 | 39K |
| 2026-06-11 | Johnson David Michael | Director | Grant | 15K | $0.00 | $0 | 194K |
| 2026-06-11 | Mattessich Antony C. | Director | Grant | 15K | $0.00 | $0 | 39K |
| 2026-05-19 | Holles Natalie C. | See Remarks | Grant | 554K | $0.00 | $0 | 1.2M |
| 2026-05-19 | Holles Natalie C. | See Remarks | Grant | 600K | $0.00 | $0 | 600K |
| 2026-05-07 | Matrix Capital Management Company, LP | 10% owner | Sell | 6.9M | $5.64 | $39.0M | 0 |
| 2026-04-16 | Kilroy Conor | See Remarks | Sell | 12K | $7.02 | $82K | 218K |
| 2026-03-02 | Kilroy Conor | See Remarks | Grant | 62K | $0.00 | $0 | 230K |
| 2026-03-02 | Gibney Anthony S | See Remarks | Grant | 71K | $0.00 | $0 | 278K |
| 2026-03-02 | de los Pinos Elisabet | See Remarks | Grant | 166K | $0.00 | $0 | 576K |
| 2026-03-02 | Plavsic Mark | Chief Technology Officer | Grant | 62K | $0.00 | $0 | 244K |
| 2026-03-02 | Hopkins Janet Jill | Chief Medical Officer | Grant | 89K | $0.00 | $0 | 321K |
| 2026-03-02 | Elazzouzi Amy | Senior Vice President, Finance | Grant | 45K | $0.00 | $0 | 120K |
| 2026-02-17 | Kilroy Conor | See Remarks | Sell | 12K | $5.05 | $61K | 167K |
| 2026-02-17 | Plavsic Mark | Chief Technology Officer | Sell | 16K | $5.05 | $80K | 181K |
| 2026-02-17 | Hopkins Janet Jill | Chief Medical Officer | Sell | 20K | $5.06 | $103K | 232K |
| 2026-02-17 | Elazzouzi Amy | Senior Vice President, Finance | Sell | 9K | $5.06 | $43K | 76K |
| 2026-02-17 | de los Pinos Elisabet | See Remarks | Sell | 48K | $5.06 | $241K | 410K |
| 2026-01-20 | Elazzouzi Amy | Senior Vice President, Finance | Sell | 2K | $4.86 | $8K | 84K |
| 2026-01-20 | de los Pinos Elisabet | See Remarks | Sell | 17K | $4.86 | $82K | 457K |
| 2025-11-17 | Hopkins Janet Jill | Chief Medical Officer | Sell | 17K | $5.42 | $93K | 253K |
| 2025-10-29 | Elazzouzi Amy | Senior Vice President, Finance | Sell | 896 | $6.35 | $6K | 86K |
| 2025-10-29 | de los Pinos Elisabet | See Remarks | Sell | 9K | $6.35 | $57K | 474K |
| 2025-10-16 | Plavsic Mark | Chief Technology Officer | Sell | 12K | $6.35 | $77K | 197K |
| 2025-08-18 | Elazzouzi Amy | Senior Vice President, Finance | Exercise or conversion | 1K | $3.16 | $3K | 92K |
| 2025-08-18 | Elazzouzi Amy | Senior Vice President, Finance | Exercise or conversion | 547 | $5.21 | $3K | 86K |
| 2025-08-18 | Elazzouzi Amy | Senior Vice President, Finance | Sell | 8K | $6.70 | $52K | 87K |
| 2025-08-18 | Elazzouzi Amy | Senior Vice President, Finance | Exercise or conversion | 2K | $4.25 | $10K | 94K |
| 2025-08-18 | Elazzouzi Amy | Senior Vice President, Finance | Exercise or conversion | 5K | $2.74 | $13K | 91K |
| 2025-08-18 | Elazzouzi Amy | Senior Vice President, Finance | Exercise or conversion | 547 | $5.48 | $3K | 86K |
| 2025-08-18 | Elazzouzi Amy | Senior Vice President, Finance | Exercise or conversion | 1K | $5.48 | $6K | 85K |
| 2025-08-18 | Elazzouzi Amy | Senior Vice President, Finance | Exercise or conversion | 3K | $5.07 | $13K | 84K |
| 2025-06-17 | Srivastava Sapna | Director | Grant | 13K | $0.00 | $0 | 24K |
| 2025-06-17 | Johnson David Michael | Director | Grant | 13K | $0.00 | $0 | 179K |
| 2025-06-17 | Mattessich Antony C. | Director | Grant | 13K | $0.00 | $0 | 24K |
| 2025-06-02 | de los Pinos Elisabet | See Remarks | Tax withholding | 10K | $6.16 | $61K | 483K |
| 2025-06-02 | de los Pinos Elisabet | See Remarks | Exercise or conversion | 11K | $5.07 | $56K | 493K |
| 2025-06-02 | Gibney Anthony S | See Remarks | Grant | 150K | $0.00 | $0 | 207K |
| 2025-05-16 | Gibney Anthony S | See Remarks | Sell | 2K | $5.15 | $8K | 57K |
| 2025-05-16 | Gibney Anthony S | See Remarks | Buy | 50K | $4.90 | $245K | 58K |
| 2025-05-16 | Johnson David Michael | Director | Buy | 20K | $4.90 | $98K | 166K |
| 2025-04-16 | Kilroy Conor | See Remarks | Sell | 7K | $5.49 | $39K | 179K |
| 2025-04-16 | Elazzouzi Amy | Senior Vice President, Finance | Sell | 897 | $5.49 | $5K | 81K |
| 2025-03-31 | Bitetti Teresa Marie | Director | Grant | 21K | $0.00 | $0 | 21K |
| 2025-02-18 | de los Pinos Elisabet | See Remarks | Sell | 20K | $7.75 | $157K | 482K |
| 2025-02-18 | Hopkins Janet Jill | Chief Medical Officer | Sell | 3K | $7.75 | $20K | 270K |
| 2025-02-18 | Elazzouzi Amy | Senior Vice President, Finance | Sell | 1K | $7.75 | $11K | 82K |
| 2025-02-18 | Plavsic Mark | Chief Technology Officer | Sell | 2K | $7.75 | $17K | 209K |
| 2025-02-03 | Elazzouzi Amy | Senior Vice President, Finance | Grant | 45K | $0.00 | $0 | 84K |
| 2025-02-03 | Kilroy Conor | See Remarks | Grant | 90K | $0.00 | $0 | 186K |
| 2025-02-03 | Hopkins Janet Jill | Chief Medical Officer | Grant | 121K | $0.00 | $0 | 272K |
| 2025-02-03 | Plavsic Mark | Chief Technology Officer | Grant | 90K | $0.00 | $0 | 212K |
| 2025-02-03 | de los Pinos Elisabet | See Remarks | Grant | 194K | $0.00 | $0 | 503K |
| 2025-01-21 | Elazzouzi Amy | Vice President, Finance | Sell | 1K | $7.67 | $8K | 38K |
| 2025-01-21 | de los Pinos Elisabet | See Remarks | Sell | 16K | $7.67 | $122K | 305K |
| 2024-11-18 | Hopkins Janet Jill | Chief Medical Officer | Sell | 12K | $9.36 | $111K | 152K |
| 2024-10-29 | Elazzouzi Amy | Vice President, Finance | Sell | 553 | $10.74 | $6K | 39K |
| 2024-10-29 | de los Pinos Elisabet | See Remarks | Sell | 9K | $10.74 | $99K | 321K |
| 2024-10-18 | de los Pinos Elisabet | See Remarks | Sell | 25K | $12.04 | $301K | 330K |
| 2024-10-18 | de los Pinos Elisabet | See Remarks | Exercise or conversion | 25K | $2.74 | $68K | 355K |
| 2024-10-18 | Feder Julie B | Chief Financial Officer | Exercise or conversion | 5K | $5.48 | $27K | 159K |
| 2024-10-18 | Feder Julie B | Chief Financial Officer | Exercise or conversion | 3K | $4.25 | $11K | 154K |
| 2024-10-18 | Feder Julie B | Chief Financial Officer | Exercise or conversion | 18K | $2.74 | $48K | 152K |
| 2024-10-18 | Feder Julie B | Chief Financial Officer | Sell | 25K | $12.03 | $302K | 134K |
| 2024-10-16 | Plavsic Mark | Chief Technology Officer | Sell | 7K | $9.85 | $73K | 121K |
| 2024-09-27 | de los Pinos Elisabet | See Remarks | Exercise or conversion | 5K | $5.76 | $32K | 330K |
| 2024-06-20 | Johnson David Michael | Director | Grant | 11K | $0.00 | $0 | 146K |
| 2024-06-20 | Srivastava Sapna | Director | Grant | 11K | $0.00 | $0 | 11K |
| 2024-06-20 | Mattessich Antony C. | Director | Grant | 11K | $0.00 | $0 | 11K |
| 2024-04-02 | Kilroy Conor | General Counsel and Secretary | Grant | 96K | $0.00 | $0 | 96K |
| 2024-02-01 | de los Pinos Elisabet | See Remarks | Grant | 163K | $0.00 | $0 | 324K |
| 2024-02-01 | Feder Julie B | Chief Financial Officer | Grant | 71K | $0.00 | $0 | 134K |
| 2024-02-01 | Hopkins Janet Jill | Chief Medical Officer | Grant | 29K | $0.00 | $0 | 164K |
| 2024-01-23 | Feder Julie B | Chief Financial Officer | Sell | 7K | $7.64 | $50K | 63K |
| 2024-01-23 | de los Pinos Elisabet | See Remarks | Sell | 16K | $7.64 | $121K | 161K |
| 2023-11-09 | Matrix Capital Management Company, LP | TenPercentOwner | Buy | 1.6M | $9.00 | $14.0M | 6.9M |
| 2023-11-08 | Johnson David Michael | Director | Buy | 10K | $7.30 | $73K | 75K |
| 2023-11-08 | Johnson David Michael | Director | Buy | 10K | $7.30 | $70K | 136K |
| 2023-11-08 | Johnson David Michael | Director | Buy | 10K | $7.30 | $73K | 75K |
| 2023-11-07 | Johnson David Michael | Director | Buy | 47K | $7.17 | $337K | 65K |
| 2023-11-07 | Johnson David Michael | Director | Buy | 76K | $7.17 | $545K | 126K |
| 2023-11-07 | Johnson David Michael | Director | Buy | 47K | $7.17 | $337K | 65K |
| 2023-11-06 | Feder Julie B | Chief Financial Officer | Exercise or conversion | 4K | $2.74 | $11K | 74K |
| 2023-11-06 | Feder Julie B | Chief Financial Officer | Sell | 4K | $12.07 | $47K | 70K |
| 2023-11-06 | de los Pinos Elisabet | See Remarks | Exercise or conversion | 4K | $2.74 | $10K | 185K |
| 2023-11-06 | de los Pinos Elisabet | See Remarks | Sell | 7K | $12.03 | $90K | 177K |
| 2023-11-01 | Hopkins Janet Jill | Chief Medical Officer | Grant | 135K | $0.00 | $0 | 135K |
| 2023-10-30 | de los Pinos Elisabet | See Remarks | Sell | 10K | $6.83 | $65K | 181K |
| 2023-10-30 | Feder Julie B | Chief Financial Officer | Sell | 3K | $6.82 | $23K | 70K |
| 2023-10-04 | Johnson David Michael | Director | Buy | 7K | $8.61 | $57K | 50K |
| 2023-10-03 | Johnson David Michael | Director | Buy | 14K | $8.27 | $112K | 44K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON13 Form 144 notices on file for AURA worth $1.0M at the prices reported; 0 in the last 90 days worth $0. Latest: Gibney Anthony filed on 2026-06-16 to sell 12,824 shares ($82K) from 2026-06-16.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-06-16 | Gibney AnthonyOfficer | 13K | $82K | 0.012% | 2026-06-16 | Morgan Stanley Smith Barney LLC Drive |
| 2026-04-16 | Kilroy ConorOfficer | 12K | $82K | 0.018% | 2026-04-16 | Morgan Stanley Smith Barney LLC Drive |
| 2026-02-17 | Kilroy ConorOfficer | 12K | $61K | 0.019% | 2026-02-17 | Morgan Stanley Smith Barney LLC Drive |
| 2026-02-17 | Plavsic MarkOfficer | 16K | $80K | 0.025% | 2026-02-17 | Morgan Stanley Smith Barney LLC Drive |
| 2026-02-17 | Hopkins Janet JillOfficer | 20K | $103K | 0.032% | 2026-02-17 | Morgan Stanley Smith Barney LLC Drive |
| 2026-02-17 | Elazzouzi AmyOfficer | 9K | $43K | 0.013% | 2026-02-17 | Morgan Stanley Smith Barney LLC Drive |
| 2026-02-17 | de los Pinos ElisabetOfficer, Director | 48K | $241K | 0.075% | 2026-02-17 | Morgan Stanley Smith Barney LLC Drive |
| 2026-01-20 | Elazzouzi AmyOfficer | 2K | $8K | 0.002% | 2026-01-20 | Morgan Stanley Smith Barney LLC Drive |
| 2026-01-20 | de los Pinos ElisabetOfficer, Director | 17K | $82K | 0.027% | 2026-01-20 | Morgan Stanley Smith Barney LLC Drive |
| 2025-11-17 | Hopkins Janet JillOfficer | 17K | $93K | 0.027% | 2025-11-17 | Morgan Stanley Smith Barney LLC Drive |
| 2025-10-29 | Elazzouzi AmyOfficer | 896 | $6K | 0.001% | 2025-10-29 | Morgan Stanley Smith Barney LLC Drive |
| 2025-10-29 | de los Pinos ElisabetOfficer, Director | 9K | $57K | 0.015% | 2025-10-29 | Morgan Stanley Smith Barney LLC Drive |
| 2025-10-16 | Plavsic MarkOfficer | 12K | $77K | 0.020% | 2025-10-16 | Morgan Stanley Smith Barney LLC Drive |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON15 holders report 5% or more of AURA in their latest filing, all on Schedule 13G (passive). The largest reported stake is Chen Yu at 9.9% of the class (9,533,333 shares), filed 2026-05-12 for an event on 2026-05-05.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-27 | 13G | BlackRock, Inc.parent holding company | 5.2M | 5.0% | 2026-09-30 |
| 2026-10-01 | 13G | Forbion Growth III Management B.V.other entity | 5.2M | 5.1% | 2026-09-25 |
| 2026-10-01 | 13G | Forbion Growth Opportunities Fund III Cooperatief U.A.other entity | 5.2M | 5.1% | 2026-09-25 |
| 2026-10-01 | 13G | ForGrowth III PA B.V.other entity | 5.2M | 5.1% | 2026-09-25 |
| 2026-08-14 | 13G/Ano. 3 | FHMLSP, L.L.C.other entity | 5.8M | 5.6% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 3 | Frazier Life Sciences Public Fund, L.P.partnership | 5.8M | 5.6% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 3 | FHMLSP, L.P.partnership | 5.8M | 5.6% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 3 | Frazier Life Sciences XII, L.P.partnership | 805K | 0.8% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 3 | FHMLS XII, L.P.partnership | 805K | 0.8% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 3 | FHMLS XII, L.L.C.other entity | 805K | 0.8% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 3 | Frazier Life Sciences XI, L.P.partnership | 359K | 0.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 3 | FHMLS XI, L.P.partnership | 359K | 0.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 3 | FHMLS XI, L.L.C.other entity | 359K | 0.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 3 | James N. Topperindividual | 129K | 0.1% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 3 | Frazier Life Sciences X, L.P.partnership | 129K | 0.1% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 3 | FHMLS X, L.P.partnership | 129K | 0.1% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 3 | FHMLS X, L.L.C.other entity | 129K | 0.1% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 3 | Patrick J. Heronindividual | 129K | 0.1% | 2026-06-30 |
| 2026-08-14 | 13G | JOHN HELMERSindividual | 5.1M | 4.9% | 2026-06-30 |
| 2026-08-14 | 13G | LONG FOCUS CAPITAL MANAGEMENT, LLCinvestment adviser | 5.1M | 4.9% | 2026-06-30 |
| 2026-08-12 | 13G/Ano. 4 | Adage Capital Management, L.P.investment adviser, partnership | 9.1M | 8.4% | 2026-06-30 |
| 2026-08-12 | 13G/Ano. 4 | Robert Atchinsonparent holding company, individual | 9.1M | 8.4% | 2026-06-30 |
| 2026-08-12 | 13G/Ano. 4 | Phillip Grossparent holding company, individual | 9.1M | 8.4% | 2026-06-30 |
| 2026-05-12 | 13G | Chen Yuindividual | 9.5M | 9.9% | 2026-05-05 |
| 2026-05-12 | 13G | TCG Crossover Fund II, L.P.partnership | 4.8M | 5.0% | 2026-05-05 |
| 2026-05-12 | 13G | TCG Crossover GP III, LLCother entity | 4.8M | 5.0% | 2026-05-05 |
| 2026-05-12 | 13G | TCG Crossover GP II, LLCother entity | 4.8M | 5.0% | 2026-05-05 |
| 2026-05-12 | 13G | TCG Crossover Fund III, L.P.partnership | 4.8M | 5.0% | 2026-05-05 |
| 2026-05-11 | 13D/Ano. 4 | Matrix Capital Management Company LPinvestment adviser, partnership | 0 | 0.0% | 2026-05-07 |
| 2026-05-11 | 13D/Ano. 4 | David E. Goelindividual, parent holding company | 0 | 0.0% | 2026-05-07 |
| 2026-02-17 | 13G/Ano. 1 | Rajesh Parekh, Ph.D.individual | 2.1M | 3.3% | 2026-02-13 |
| 2026-02-17 | 13G/Ano. 1 | Advent-Harrington Impact Fund LPpartnership | 2.0M | 3.3% | 2026-02-13 |
| 2026-02-17 | 13G/Ano. 1 | Advent Life Sciences LLPpartnership | 2.0M | 3.3% | 2026-02-13 |
| 2026-02-17 | 13G/Ano. 1 | Advent Life Sciences Fund I LPpartnership | 2.0M | 3.3% | 2026-02-13 |
| 2026-02-17 | 13G/Ano. 1 | Advent Life Sciences Fund III LPpartnership | 2.0M | 3.3% | 2026-02-13 |
| 2026-02-17 | 13G/Ano. 1 | ALS III Carry and Co-Invest LPpartnership | 2.0M | 3.3% | 2026-02-13 |
13F holders
Tracked managers holding AURA at their latest 13F. JSON7 of the 30 tracked managers held AURA at their latest 13F, $8.0M in total at quarter-end prices. Millennium Management is the largest at $4.4M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 4 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Millennium Management | 2026-06-30 | 617K | $4.4M | 0.00% | -480K |
| Renaissance Technologies | 2026-06-30 | 174K | $1.2M | 0.00% | +72K |
| AQR Capital Management | 2026-06-30 | 110K | $780K | 0.00% | +64K |
| Fisher Asset Management | 2026-06-30 | 84K | $593K | 0.00% | 0 |
| D. E. Shaw & Co. | 2026-06-30 | 67K | $479K | 0.00% | new |
| Citadel Advisors | 2026-06-30 | 52K | $369K | 0.00% | +39K |
| Point72 Asset Management | 2026-06-30 | 18K | $127K | 0.00% | -4K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Aura Biosciences in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Aura Biosciences (AURA), SEC CIK 1501796, listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-14.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-06-16.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-27.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-11.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-01.JSON and CSV
- Company record
- EDGAR filing index for CIK 1501796Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as biological products, (no diagnostic substances)
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of AURA is sold short?
10,885,962 shares were held short at the 2026-10-15 settlement, 10.6 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is AURA's daily short volume?
On 2026-11-02, 167,028 of the 239,060 AURA shares reported to FINRA were sold short, 69.9% of the day's reported volume. Short volume is a flow for one day, not a position.
Does AURA have fails to deliver?
The SEC's latest file shows 8,026 AURA shares failed to deliver at settlement 2026-10-14. Fails are reported per settlement date and published twice a month with a lag.
Are AURA insiders buying or selling?
No open-market insider trades were reported for AURA in the last 90 days. The most recent filings are listed below. Latest filing: Kratz Erica (Chief Reg. & Quality Officer) on 2026-09-01.
Have AURA insiders filed to sell?
13 Form 144 notices on file for AURA worth $1.0M at the prices reported; 0 in the last 90 days worth $0. Latest: Gibney Anthony filed on 2026-06-16 to sell 12,824 shares ($82K) from 2026-06-16.
Who owns 5% or more of AURA?
15 holders report 5% or more of AURA in their latest filing, all on Schedule 13G (passive). The largest reported stake is Chen Yu at 9.9% of the class (9,533,333 shares), filed 2026-05-12 for an event on 2026-05-05.
Which tracked 13F managers own AURA?
7 of the 30 tracked 13F managers held AURA shares at their latest filing, $8.0M in all. The largest: Izzy Englander's Millennium Management (617K shares, $4.4M), Renaissance Technologies (174K shares, $1.2M), Cliff Asness's AQR Capital Management (110K shares, $780K), Ken Fisher's Fisher Asset Management (84K shares, $593K), D. E. Shaw & Co. (67K shares, $479K), Ken Griffin's Citadel Advisors (52K shares, $369K). The table above lists all 7.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.